4SC AG RSI
¿Qué es el RSI de 4SC AG?
El RSI de 4SC AG es 80.28
¿Cuál es la definición de RSI?
El índice de fortaleza relativa (RSI 14) es un indicador de impulso que compara la magnitud de las ganancias y pérdidas durante un período de tiempo específico para medir la velocidad y el cambio de los movimientos de precios de un valor.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de compañías en Sector Health Care en XETRA en comparadas con 4SC AG
¿Qué hace 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Empresas con rsi similar a 4SC AG
- CuriosityStream tiene RSI de 80.24
- iShares VI Public - iShares Euro Corporate Bond s UCITS ETF tiene RSI de 80.24
- Ventus 2 VCT Plc tiene RSI de 80.24
- Amego Capital Corp tiene RSI de 80.26
- Kamdhenu tiene RSI de 80.27
- IGG Inc tiene RSI de 80.27
- 4SC AG tiene RSI de 80.28
- ScandiVanadium Ltd tiene RSI de 80.29
- Hawthorn Bancshares Inc tiene RSI de 80.29
- Ceps Plc tiene RSI de 80.30
- New England Realty Associates LP tiene RSI de 80.30
- Zhong Ao Home tiene RSI de 80.31
- Rama Steel Tubes tiene RSI de 80.31